By Zeev Estrov (auth.), Lalitha Nagarajan (eds.)
Acute myelogenous leukemia (AML), is the commonest kind of leukemia in adults. AML is a dangerous kind of malignancy, the analysis for which has no longer greater within the final twenty years. extra importantly, it's a malignancy that's obvious in older adults, for that reason the variety of circumstances is probably going to upward thrust because the inhabitants a while.
Over the previous 15 years, genetic mechanisms underlying AML have started to spread. extra learn during this zone has helped establish key parts and features. as a result, certain treatment of AML is receiving a lot recognition. it's the desire of researchers that as with continual myelogenous leukemia (CML), and the drug, Gleevec, a designated remedy for AML may be discovered.
"The powerful remedy of acute myelogenous leukemia continues to be an exceptional problem. this article experiences our figuring out of the molecular and biologic foundation of the illness. top investigators tackle advances in prognostication and healing techniques that experience major promise."
Steven T. Rosen, M.D.
Read or Download Acute Myelogenous Leukemia: Genetics, Biology and Therapy PDF
Best biophysics books
Jack Tar's tale examines the autobiographies and memoirs of antebellum American sailors to discover contested meanings of manhood and nationalism within the early republic. it's the first learn to exploit several types of institutional assets, together with staff lists, ships' logs, impressment files, to record the tales sailors advised.
Recounting the social, cultural, and medical background of vaccines, Vaccines: A Biography lines the lineage—the ‘biography’—of person vaccines, originating with deeply rooted scientific difficulties, following principles as they're conceived and constructed, best finally to functional, preventive options to significant public illnesses in society.
Die vorliegende Schrift von Martina Goblirsch basiert auf ihrer Dissertation und steht in der culture einer in der Sozialpadagogik und Soziologie gleichermassen anerkannten biographieanalytischen culture. Dabei handelt es sich keineswegs nur um ein biographisches Studiendesign zu einem Gegenstandsbereich Sozialer Arbeit.
- Electrical Phenomena at Interfaces and Biointerfaces: Fundamentals and Applications in Nano-, Bio-, and Environmental Sciences
- Bone and Development
- Bone Disease of Organ Transplantation
- Biotecnologia de la cervenza y de la malta
- The Palgrave Macmillan Dictionary of Women's Biography: Fourth Edition
Additional resources for Acute Myelogenous Leukemia: Genetics, Biology and Therapy
2004;279(26):27816–27823. 148. Szyf M, Bozovic V, Tanigawa G. Growth regulation of mouse DNA methyltransferase gene expression. J Biol Chem. 1991;266(16):10027–10030. 149. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 2001;414(6861):277–283. 150. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71(4):691–700. 151. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP.
Leukemia. 2005;19(8):1367–1375. 81. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074–1080. 82. Jin F, Dowdy SC, Xiong Y, Eberhardt NL, Podratz KC, Jiang SW. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol Oncol. 2005;96(2): 531–538. 83. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4(1):13–8. 84. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer.
J. Issa 75. Issa JP. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol. 1999;32(1):31–43. 76. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12): 988–993. 77. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-20 -deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635–1640. 78. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Acute Myelogenous Leukemia: Genetics, Biology and Therapy by Zeev Estrov (auth.), Lalitha Nagarajan (eds.)